Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

N Spine Inc.

This article was originally published in Start Up

Executive Summary

N Spine Inc. is entering the hot dynamic stabilization market with a second-generation pedicle screw system. The company's technology has the unique ability to elongate and compress, enabling patients' spines to flex and extend in a manner close to natural physiologic movement while at the same time stabilizing shear and axial rotation.

You may also be interested in...



Spine Market: Are the Good Times Over?

The global market for spine implants and products will surpass $6 billion this year. While technological innovations continue to abound and industry proponents forecast sustained double-digit growth, the spine market is entering an unsettling phase of bureaucratic regulation and oversight from regulators and payors who appear intent on putting the breaks on this sector.

Business & Technology Briefs (11/2007)

Brief summaries of recent product and company developments in the device industry, including: poor acceptance dooms Exubera inhaled insulin; QLT bets big on ForSight plug; hot markets, lukewarm IPOs; Arteriocyte Medical launches; Synthes buys N Spine.

Business & Technology Briefs (11/2007)

Brief summaries of recent product and company developments in the device industry, including: poor acceptance dooms Exubera inhaled insulin; QLT bets big on ForSight plug; hot markets, lukewarm IPOs; Arteriocyte Medical launches; Synthes buys N Spine.

Related Content

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC091432

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel